Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Journal: eLife

Published: 2020-11-17

DOI: 10.7554/elife.58376

Affiliations: 9

Authors: 21

Go to article
Institutions Share
Pfizer Inc., United States of America (USA) 0.90
Yale University, United States of America (USA) 0.05
Acceleron Pharma, Inc., United States of America (USA) 0.02
Eisai Inc., United States of America (USA) 0.02

Return